GMABGenmab A/S

$33.75

What is the market doing?

What the tape says about GMAB

Genmab A/S is +49% over the past year while the S&P 500 is +23%: 26 points ahead of the market.

+49%

1-year return · S&P 500 +23%

vs 200-day average
+15%

vs 200-day average · a clear uptrend

RSI (14)
73

RSI (14) · overbought, bought harder than it has been sold

Below its 52-week high
−4.5%

Below its 52-week high

2024-08-06$17.98 – $35.34 · dashed line: 200-day average2026-08-26
Details
Last close2026-08-26
$33.75
1 monthS&P 500 +3.7%
+16%
1 yearS&P 500 +23%
+49%
5 yearsS&P 500 +87%
−25%
vs 50-day average$28.48
+18%
52-week high
$35.34
52-week low
$21.08
Annualised volatility
35%
Calendar-year price return
YearReturn
2026 (year to date)+9.6%
2025+48%
2024−34%
2023−25%
2022+7.1%
2021−2.7%
2020+82%
2019+36%
2018−0.61%
2017−0.04%
Average return by calendar month, 2016–2026
MonthYearsPositiveAverage
Jan104 of 10−1.6%
Feb105 of 10+1.7%
Mar105 of 10−1.4%
Apr105 of 10+2.4%
May105 of 10+0.35%
Jun106 of 10+1.1%
Jul119 of 11+6.9%
Aug117 of 11+3.6%
Sep102 of 10−2.5%
Oct103 of 10−3.7%
Nov107 of 10+6.4%
Dec104 of 10−2.6%

End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.